NICOLE MARTIN: Open Payments
NPI 1730645862 · HUNTSVILLE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,039 in 116 payments from 25 companies in 2025. Trend: 2023 $300 · 2024 $523 · 2025 $2,039
Food & beverage: $2,039
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 20 | $368 |
| PFIZER INC. | 32 | $278 |
| Neurocrine BioSciences, Inc. | 8 | $195 |
| Neurelis, Inc. | 6 | $104 |
| Otsuka America Pharmaceutical, Inc. | 4 | $96 |
| ARGENX US, INC. | 3 | $94 |
| UCB, Inc. | 3 | $92 |
| Janssen Biotech, Inc. | 3 | $85 |
| Amgen Inc. | 5 | $81 |
| Alexion Pharmaceuticals, Inc. | 4 | $79 |
Products named: KESIMPTA, NURTEC ODT, INGREZZA, VALTOCO, REXULTI, UPLIZNA, ULTOMIRIS, NUPLAZID.
Industry payments across AL — which companies pay providers there.
